Related Experiment Video
Updated: Jul 12, 2026
09:19
RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes
Published on: July 22, 2014
Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation
M J Pröpsting1, M Blaschke, R E Haas
1Department of Gastroenterologie and Hepatologie, Medical School Hannover, Hannover, D-30623, Germany.
Biochemical and Biophysical Research Communications
|July 15, 1999
Summary
Researchers developed a specific hammerhead ribozyme to cleave TTR-met30 mRNA, offering a potential therapy for hereditary amyloidosis caused by the transthyretin val30met mutation.
Area of Science:
- Molecular Biology
- Biochemistry
- Genetics
Background:
- Hereditary amyloidosis (HA) is commonly caused by the val30met mutation in the transthyretin protein (TTR-met30).
- This mutation arises from a G-to-A substitution in the transthyretin gene, altering the protein sequence.
- Current therapeutic strategies for HA are limited.
Purpose of the Study:
- To develop a specific method for cleaving TTR-met30 messenger RNA (mRNA).
- To engineer hammerhead ribozymes for targeted degradation of the mutated TTR mRNA.
- To assess the efficacy and specificity of the engineered ribozymes in vitro.
Main Methods:
- Chemical modification of hammerhead ribozymes to enhance nuclease stability.
- Modification of the ribozyme's catalytic core by replacing adenosine with inosine at position 15.1.
- In vitro cleavage assays using TTR-met30 mRNA and wildtype TTR mRNA.
Main Results:
- The modified inosine(15.1) hammerhead ribozyme specifically targeted and cleaved TTR-met30 mRNA.
- Cleavage occurred with 100% specificity and a reaction velocity of 0.23 min⁻¹.
- No cleavage of wildtype TTR mRNA was observed, demonstrating high specificity.
Conclusions:
- The developed NCH-specific hammerhead ribozyme is a highly effective tool for targeting TTR-met30 mRNA.
- This ribozyme shows promise for future in vivo therapeutic applications in hereditary amyloidosis.
- The findings offer a potential new avenue for treating TTR-met30 induced hereditary amyloidosis.
Related Concept Videos
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:47Ribozymes
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
Ribozymes can be...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
02:47Ribozymes
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
Ribozymes can be...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...